Heim49B • FRA
add
Beigene Ltd
Við síðustu lokun
15,33 €
Dagbil
15,34 € - 15,34 €
Árabil
8,90 € - 20,20 €
Markaðsvirði
208,88 ma. HKD
Meðalmagn
37,00
V/H-hlutf.
-
A/V-hlutfall
-
Í fréttum
688235
0,54%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD) | des. 2024info | Breyting á/á |
---|---|---|
Tekjur | 1,19 ma. | 84,84% |
Rekstrarkostnaður | 1,09 ma. | 19,51% |
Nettótekjur | -139,70 m. | 58,27% |
Hagnaðarhlutfall | -11,75 | 77,43% |
Hagnaður á hvern hlut | -0,80 | -196,59% |
EBITDA | -33,25 m. | 90,73% |
Virkt skatthlutfall | -112,84% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(USD) | des. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 2,63 ma. | -17,16% |
Heildareignir | 5,92 ma. | 1,99% |
Heildarskuldir | 2,59 ma. | 14,14% |
Eigið fé alls | 3,33 ma. | — |
Útistandandi hlutabréf | 106,72 m. | — |
Eiginfjárgengi | 0,49 | — |
Arðsemi eigna | -3,26% | — |
Ávöxtun eigin fjár | -4,29% | — |
Peningaflæði
Breyting á handbæru fé
(USD) | des. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | -139,70 m. | 58,27% |
Handbært fé frá rekstri | 111,61 m. | 128,21% |
Reiðufé frá fjárfestingum | -247,31 m. | 26,86% |
Reiðufé frá fjármögnun | 30,05 m. | -92,11% |
Breyting á handbæru fé | -155,64 m. | 57,59% |
Frjálst peningaflæði | 434,97 m. | 505,95% |
Um
BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in the Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November, 2024 the company announced its intention to rebrand as BeOne Medicines. Wikipedia
Framkvæmdastjóri
Stofnsett
28. okt. 2010
Vefsvæði
Starfsfólk
11.000